208 related articles for article (PubMed ID: 22060015)
21. Induction of a specific CD8+ T-cell response to cancer/testis antigens by demethylating pre-treatment against osteosarcoma.
Li B; Zhu X; Sun L; Yuan L; Zhang J; Li H; Ye Z
Oncotarget; 2014 Nov; 5(21):10791-802. PubMed ID: 25301731
[TBL] [Abstract][Full Text] [Related]
22. Treatment of ovarian cancer cell lines with 5-aza-2'-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules.
Adair SJ; Hogan KT
Cancer Immunol Immunother; 2009 Apr; 58(4):589-601. PubMed ID: 18791715
[TBL] [Abstract][Full Text] [Related]
23. IL-15 mediated expansion of rare durable memory T cells following adoptive cellular therapy.
Kohli K; Yao L; Nowicki TS; Zhang S; Black RG; Schroeder BA; Farrar EA; Cao J; Sloan H; Stief D; Cranmer LD; Wagner MJ; Hawkins DS; Pillarisetty VG; Ribas A; Campbell J; Pierce RH; Kim EY; Jones RL; Riddell SR; Yee C; Pollack SM
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963013
[TBL] [Abstract][Full Text] [Related]
24. Decitabine enhances targeting of AML cells by NY-ESO-1-specific TCR-T cells and promotes the maintenance of effector function and the memory phenotype.
Kang S; Wang L; Xu L; Wang R; Kang Q; Gao X; Yu L
Oncogene; 2022 Oct; 41(42):4696-4708. PubMed ID: 36097193
[TBL] [Abstract][Full Text] [Related]
25. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
[TBL] [Abstract][Full Text] [Related]
26. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
Front Immunol; 2018; 9():947. PubMed ID: 29770138
[TBL] [Abstract][Full Text] [Related]
27. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.
Yuan J; Gnjatic S; Li H; Powel S; Gallardo HF; Ritter E; Ku GY; Jungbluth AA; Segal NH; Rasalan TS; Manukian G; Xu Y; Roman RA; Terzulli SL; Heywood M; Pogoriler E; Ritter G; Old LJ; Allison JP; Wolchok JD
Proc Natl Acad Sci U S A; 2008 Dec; 105(51):20410-5. PubMed ID: 19074257
[TBL] [Abstract][Full Text] [Related]
28. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients.
Fourcade J; Kudela P; Sun Z; Shen H; Land SR; Lenzner D; Guillaume P; Luescher IF; Sander C; Ferrone S; Kirkwood JM; Zarour HM
J Immunol; 2009 May; 182(9):5240-9. PubMed ID: 19380770
[TBL] [Abstract][Full Text] [Related]
29. 5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand.
Ghanim V; Herrmann H; Heller G; Peter B; Hadzijusufovic E; Blatt K; Schuch K; Cerny-Reiterer S; Mirkina I; Karlic H; Pickl WF; Zöchbauer-Müller S; Valent P
Blood; 2012 May; 119(18):4242-52. PubMed ID: 22438247
[TBL] [Abstract][Full Text] [Related]
30. Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.
Milne K; Barnes RO; Girardin A; Mawer MA; Nesslinger NJ; Ng A; Nielsen JS; Sahota R; Tran E; Webb JR; Wong MQ; Wick DA; Wray A; McMurtrie E; Köbel M; Kalloger SE; Gilks CB; Watson PH; Nelson BH
PLoS One; 2008; 3(10):e3409. PubMed ID: 18923710
[TBL] [Abstract][Full Text] [Related]
31. Expansion of cancer germline antigen-specific cytotoxic T lymphocytes for immunotherapy.
Krishnadas DK; Wang Y; Sundaram K; Bai F; Lucas KG
Tumour Biol; 2017 Jul; 39(7):1010428317701309. PubMed ID: 28677424
[TBL] [Abstract][Full Text] [Related]
32. Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity.
Tsuji T; Matsuzaki J; Kelly MP; Ramakrishna V; Vitale L; He LZ; Keler T; Odunsi K; Old LJ; Ritter G; Gnjatic S
J Immunol; 2011 Jan; 186(2):1218-27. PubMed ID: 21149605
[TBL] [Abstract][Full Text] [Related]
33. Mediation of enhanced transcription of the IL-10 gene in T cells, upon contact with human glioma cells, by Fas signaling through a protein kinase A-independent pathway.
Yang BC; Lin HK; Hor WS; Hwang JY; Lin YP; Liu MY; Wang YJ
J Immunol; 2003 Oct; 171(8):3947-54. PubMed ID: 14530312
[TBL] [Abstract][Full Text] [Related]
34. Antigen-specific in vitro expansion of functional redirected NY-ESO-1-specific human CD8+ T-cells in a cell-free system.
Jakka G; Schuberth PC; Thiel M; Held G; Stenner F; Van Den Broek M; Renner C; Mischo A; Petrausch U
Anticancer Res; 2013 Oct; 33(10):4189-201. PubMed ID: 24122982
[TBL] [Abstract][Full Text] [Related]
35. Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma.
Batchu RB; Moreno AM; Szmania SM; Bennett G; Spagnoli GC; Ponnazhagan S; Barlogie B; Tricot G; van Rhee F
Cancer Res; 2005 Nov; 65(21):10041-9. PubMed ID: 16267030
[TBL] [Abstract][Full Text] [Related]
36. HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones.
Huarte E; Karbach J; Gnjatic S; Bender A; Jäger D; Arand M; Atanackovic D; Skipper J; Ritter G; Chen YT; Old LJ; Knuth A; Jäger E
Cancer Immun; 2004 Dec; 4():15. PubMed ID: 15600300
[TBL] [Abstract][Full Text] [Related]
37. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.
Jäger E; Chen YT; Drijfhout JW; Karbach J; Ringhoffer M; Jäger D; Arand M; Wada H; Noguchi Y; Stockert E; Old LJ; Knuth A
J Exp Med; 1998 Jan; 187(2):265-70. PubMed ID: 9432985
[TBL] [Abstract][Full Text] [Related]
38. NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine.
Pollack SM; Li Y; Blaisdell MJ; Farrar EA; Chou J; Hoch BL; Loggers ET; Rodler E; Eary JF; Conrad EU; Jones RL; Yee C
PLoS One; 2012; 7(2):e32165. PubMed ID: 22384167
[TBL] [Abstract][Full Text] [Related]
39. Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen.
Rodolfo M; Luksch R; Stockert E; Chen YT; Collini P; Ranzani T; Lombardo C; Dalerba P; Rivoltini L; Arienti F; Fossati-Bellani F; Old LJ; Parmiani G; Castelli C
Cancer Res; 2003 Oct; 63(20):6948-55. PubMed ID: 14583496
[TBL] [Abstract][Full Text] [Related]
40. Treatment with decitabine induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer: potential for combined chemoimmunotherapy.
Taib N; Merhi M; Inchakalody V; Mestiri S; Hydrose S; Makni-Maalej K; Raza A; Sahir F; Azizi F; Nizamuddin PB; Fernandes Q; Yoosuf ZSKM; Almoghrabi S; Al-Zaidan L; Shablak A; Uddin S; Maccalli C; Al Homsi MU; Dermime S
J Transl Med; 2023 Mar; 21(1):235. PubMed ID: 37004094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]